REPORT: AstraZeneca Finds Small CLOT RISK After 1st Shot of COVID-19 Vaccine

 

Here is something you probably won’t see on CNN.

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

According to Fox News, A study conducted by AstraZeneca regarding its COVID-19 vaccine found a small risk of blood clots following the first dose of the shot, but none after the second jab. The research, published Wednesday in The Lancet, comes following concerns about the shot’s safety and potential side effects.

More from Fox:

AstraZeneca said Wednesday in a news release that rates of thrombosis with thrombocytopenia (TTS) following the first dose of Vaxzevria were about 8.1 per million vaccines, while the rates following a second dose were 2.3 per million, “comparable to the background rate observed in an unvaccinated population.” 

“Vaxzevria is effective against all severities of COVID-19 and it plays a critical role in combatting the pandemic,” Sir Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said in a statement. “Unless TTS was identified after the first dose, these results support the administration of the two-dose schedule of Vaxzevria, as indicated, to help provide protection against COVID-19 including against rising variants of concern.”

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

 FULL NEWS RELEASE:

28 July 2021 07:00 BST

Incidence rates were comparable to those among unvaccinated individuals

Analysis of rare cases from global safety database published in The Lancet

Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population.

The data, published in The Lancet today, demonstrated the estimated rate of TTS following a second dose of Vaxzevria was 2.3 per million vaccinees, comparable to the background rate observed in an unvaccinated population. It was 8.1 per million vaccinees after the first dose.1 The rate after the second dose is comparable to background rates observed in unvaccinated populations.

Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “Vaxzevria is effective against all severities of COVID-19 and it plays a critical role in combatting the pandemic. Unless TTS was identified after the first dose, these results support the administration of the two-dose schedule of Vaxzevria, as indicated, to help provide protection against COVID-19 including against rising variants of concern.”

The analysis was conducted using AstraZeneca’s global safety database, which captures all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide. Reported cases of TTS globally were included up to the cut-off date of April 30 occurring within 14 days of administration of the first or second dose of Vaxzevria.

The results are in line with recent reports in the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Report, the UK system for collecting and monitoring information on safety concerns, which also show low rates of TTS after a second dose.2

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

No specific risk factors or definitive cause for TTS following COVID-19 vaccination have been identified and AstraZeneca continues to perform and support ongoing investigations of potential mechanisms. Furthermore, these very rare events can be avoided when symptoms are identified and treated appropriately.3

Vaxzevria, formerly AZD1222
Vaxzevria was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 80 countries across six continents. More than 800 million doses of COVID-19 Vaccine AstraZeneca have been supplied to more than 170 countries worldwide, including more than 100 countries through the COVAX Facility.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF


References

1. Bhuyan P., et al., (2021) Thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis of rare cases. The Lancet. Published Online: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01693-7/fulltext
2. MHRA. Coronavirus vaccine – weekly summary of Yellow Card reporting – GOV.UK 1 July Update. Available at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
3. Bussel, J.B., et al. (2021) Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia): https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

[SUPPORT MIKE AND MY PILLOW] use code THANKS45 for up to 66 % OFF

AT THIS POINT YOU’VE PROBABLY HEARD ALL SORTS OF DIFFERENT THINGS ABOUT THE FREEDOM PHONE.

Use code MAGA to save $50 and fight big tech!
The Blue Checkmark Brigade have come out in full force just like we knew that they would. After all, they can’t stand the idea of not having an iron grip on all your information. They don’t want Conservatives to have anything that prevents the big tech oligarchs from spying, censoring, and banning anything that isn’t “politically correct” or is “out of context” as Facebook loves to say as an excuse for suppression.
Use code MAGA to save $50 and fight big tech!
One of the many perks about the phone is that it’s hassle-free. No having to make a trip to go deal with your provider, you keep the same service you’ve always had. All you have to do is take the SIM card out of your old phone and pop it into SIM card slot in the Freedom Phone.  It’s really is that easy to get your privacy back. And the dual SIM card slots are so that you can add additional storage for things like photos, videos, or anything you want! It’s a free country after all.
Use code MAGA to save $50 and fight big tech!
First, The Daily Beast wrote an article saying that the Freedom Phone is, “just a budget Chinese phone“. This couldn’t be further from the truth. While it is an incredible deal, a mere $449.99 with code “MAGA” (compared to a $700-$1000 iPhone12) it IS NOT manufactured in China. Although the Daily Beast might have a “one-China policy” The Freedom Phone is actually manufactured in Hong Kong. You’ll remember Hong Kong from the HUGE protests where they waved American flags and fought hard against the authoritarian Chinese government who was trying to take control of their country. Patriots recognize Patriots, and that’s why Freedom Phone is PROUD to have their product manufactured in a country that is actually fighting with boots on the ground against one of the biggest enemies of the USA.
Use code MAGA to save $50 and fight big tech!
 
You Might Like